https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-10 / J. Viral Hepat. 2008 Nov;15(11):782-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-10 / J. Viral Hepat. 2008 Nov;15(11):782-92008-07-10 00:00:002019-02-15 08:37:35Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-09 / Vaccine 2008 Aug;26(36):4716-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-09 / Vaccine 2008 Aug;26(36):4716-242008-07-09 00:00:002023-03-07 13:11:25Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-742008-07-01 00:00:002019-02-15 08:44:34Maximizing dendritic cell migration in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-5002008-07-01 00:00:002019-02-15 09:19:20Strategies to overcome obstacles to successful immunotherapy of melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-512008-07-01 00:00:002019-02-15 09:19:24Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-412008-07-01 00:00:002019-02-15 09:19:25Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-622008-07-01 00:00:002019-02-15 09:19:26IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-82008-07-01 00:00:002019-02-15 09:19:26Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-305
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-3052008-07-01 00:00:002019-02-15 08:53:22Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Hepatology 2008 Jul;48(1):157-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Hepatology 2008 Jul;48(1):157-682008-07-01 00:00:002008-07-01 00:00:00CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo
